This article was accepted for publication after full peer-review.
Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials
Article first published online: 3 APR 2014
© 2014 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Alimentary Pharmacology & Therapeutics
Volume 39, Issue 10, pages 1161–1168, May 2014
How to Cite
Schoenfeld, P., Pimentel, M., Chang, L., Lembo, A., Chey, W. D., Yu, J., Paterson, C., Bortey, E. and Forbes, W. P. (2014), Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Alimentary Pharmacology & Therapeutics, 39: 1161–1168. doi: 10.1111/apt.12735
- Issue published online: 16 APR 2014
- Article first published online: 3 APR 2014
- Manuscript Accepted: 15 MAR 2014
- Manuscript Revised: 14 MAR 2014
- Manuscript Revised: 19 OCT 2013
- Manuscript Received: 3 OCT 2013
- Salix Pharmaceuticals, Inc.
- 7Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (NY) 2011; 7: 455–93., , , .
- 8Xifaxan (rifaximin) tablets [package insert]. Raleigh, NC: Salix Pharmaceuticals, Inc., 2012.
- 10Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology 2008; 134: A–545., , , et al.
- 11ClinicalTrials.gov. Study to assess the efficacy and safety of rifaximin administered BID in the treatment of patients with diarrhea-associated irritable bowel syndrome. Clinicaltrials.gov. December 21, 2009. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00269412?term=rifaximin+IBS&rank=9. Accessed January 15, 2013.
- 19Gastrointestinal Drugs Advisory Committee. XIFAXAN® (Rifaximin) Tablets, 550 Mg, NDA 21-361: Briefing Document for Gastrointestinal Drugs Advisory Committee Meeting, 16 November 2011. Silver Springs, MD: U.S. Department of Health & Human Services; U.S. Food and Drug Administration, 2011. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/gastrointestinaldrugsadvisorycommittee/ucm279646.pdf. Accessed January 14, 2013.
- 20Rates of commonly occurring infections in cirrhosis patients remain stable during long-term rifaximin treatment. J Hepatol 2012; 56: S255–6., , , et al.
- 28Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12: 979–81., , .